Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Jens‐Uwe Blohmer's publication output changed over time?
ScholarIQpublication output · 2005–2021
Output declined50% over the shown period — from 2 works in 2005 to 1 in 2021.
2
1
1
1
3
1
2
1
20052006201020122014201720192021
What are the most-cited papers on Jens‐Uwe Blohmer?
ScholarIQmost cited works
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar, Lijun Zhang, Michael Untch, Keyur Mehta, Joseph P. Costantino, Norman Wolmark, Hervé Bonnefoi, David Cameron, Luca Gianni, Pinuccia Valagussa, Sandra M. Swain, Tatiana M. Prowell, Sibylle Loibl, D. Lawrence Wickerham, Jan Bogaerts, José Baselga, Charles M. Perou, Gideon M. Blumenthal, Jens‐Uwe Blohmer, Eleftherios P. Mamounas, Jonas Bergh, Semiglazov Vf, Robert Justice, Holger Eidtmann, Soonmyung Paik, Martine Piccart, Rajeshwari Sridhara, Peter A. Fasching, Leen Slaets, Shenghui Tang, Bernd Gerber, Charles E. Geyer, Richard Pazdur, Nina Ditsch, Priya Rastogi, W. Eiermann, Gϋnter von Minckwitz
The Lancet. 20144,765 CitationsOPEN ACCESS
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
Gϋnter von Minckwitz, Michael Untch, Jens‐Uwe Blohmer, Serban Dan Costa, Holger Eidtmann, Peter A. Fasching, Bernd Gerber, W. Eiermann, J. Hilfrich, Jens Huober, Christian Jackisch, Manfred Kaufmann, Gottfried E. Konecny, Carsten Denkert, Valentina Nekljudova, Keyur Mehta, Sibylle Loibl
Journal of Clinical Oncology. 20122,692 Citations
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
Carsten Denkert, Gϋnter von Minckwitz, Silvia Darb‐Esfahani, Bianca Lederer, Barbara Ingold Heppner, Karsten E. Weber, Jan Budczies, Jens Huober, Frederick Klauschen, Jenny Furlanetto, Wolfgang Schmitt, Jens‐Uwe Blohmer, Thomas Karn, Berit M. Pfitzner, Sherko Kümmel, Knut Engels, Andreas Schneeweiß, Arndt Hartmann, Aurelia Noske, Peter A. Fasching, Christian Jackisch, Marion van Mackelenbergh, Hans‐Peter Sinn, Christian Schem, Claus Hanusch, Michael Untch, Sibylle Loibl
The Lancet Oncology. 20172,153 Citations
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
Gϋnter von Minckwitz, Andreas Schneeweiß, Sibylle Loibl, Christoph Salat, Carsten Denkert, Mahdi Rezai, Jens‐Uwe Blohmer, Christian Jackisch, Stefan Paepke, Bernd Gerber, Dirk M. Zahm, Sherko Kümmel, Holger Eidtmann, Peter Klare, Jens Huober, Serban Dan Costa, Hans Tesch, Claus Hanusch, J. Hilfrich, F Khandan, Peter A. Fasching, Bruno V. Sinn, Knut Engels, Keyur Mehta, Valentina Nekljudova, Michael Untch
The Lancet Oncology. 20141,035 Citations
Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers
Carsten Denkert, Gϋnter von Minckwitz, Jan C. Brase, Bruno V. Sinn, Stephan Gade, Ralf Kronenwett, Berit M. Pfitzner, Christoph Salat, Sherene Loi, Wolfgang Schmitt, Christian Schem, Karin Fisch, Silvia Darb‐Esfahani, Keyur Mehta, Christos Sotiriou, Stephan Wienert, Peter Klare, Fabrice André, Frederick Klauschen, Jens‐Uwe Blohmer, Kristin Krappmann, Marcus Schmidt, Hans Tesch, Sherko Kümmel, Hans‐Peter Sinn, Christian Jackisch, Manfred Dietel, Toralf Reimer, Michael Untch, Sibylle Loibl
Journal of Clinical Oncology. 20141,031 CitationsOPEN ACCESS
Related on ScholarIQ
Charité - Universitätsmedizin Berlin
Institution
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Paper
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
Paper
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
Paper
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
Paper
Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers
Paper